ABSTRACT
INTRODUCTION
In an effort to control disease, palliate symptoms, and extend survival, several types of treatment approaches have been pursued in patients with primary liver tumors or hepatic metastases [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The Hepatic CHEMOSAT Ò Delivery System (Delcath Systems Inc., New York, NY, USA) is an innovative medical device for the treatment of patients with unresectable primary liver tumors or unresectable hepatic metastases from solid organ malignancies, in which a high dose of the chemotherapeutic agent melphalan is delivered directly to the liver while limiting systemic exposure. The concept of the procedure was developed several decades ago, but is so far not established in daily clinical practice [19] . The Hepatic CHEMOSAT Ò Delivery System received CE mark approval in the European Union (EU)
on April 13, 2011 , and the product was launched commercially in February 2012.
Promising candidates for local ablative therapies are either patients with primary liver cancers, such as hepatocellular carcinoma and cholangiocellular carcinoma, or patients with extrahepatic cancers and liver-limited disease. Hepatocellular carcinoma (HCC) is one of the most lethal and prevalent cancers worldwide. In 2008, there were 748,300 new cases of HCC and 695,900 deaths registered [20] . HCC is commonly caused by hepatitis B and C infections (*75%), chronic exposure to toxins such as aflatoxin B, non-alcoholic and alcohol steatohepatitis, or less frequently with hereditary liver diseases. The prognosis of patients with HCC is dismal and the mortality rates are almost the same as the incidence rates.
Potentially curative treatments for patients with early stage disease are liver transplantation (LT), resection, and radiofrequency or microwave ablation (RFA/MWA) [21] . Transarterial chemoembolization (TACE) is the recommended treatment for patients with intermediate stage HCC on the basis of two prospective trials with highly selected patients and one systematic review and meta-analysis [22, 23] . HCC is typically resistant to systemic chemotherapy and the multi-kinase inhibitor sorafenib is the only approved agent for patients with advanced disease. Intrahepatic cholangiocarcinoma (ICC), the second most common primary liver tumor, involves a heterogeneous group of malignancies affecting the biliary epithelium [24] . Radical resection is the only curative treatment option. In cases with a potentially curative surgery, however, 5-year survival rates of only 25-30% are reported indicating the unmet need for multimodal treatment strategies to improve the cure rate of patients with cholangiocarcinoma [25] . In metastatic disease, chemotherapy improves quality of life and survival, and gemcitabine with cisplatin represents the standard of care on the basis of recently published phase II and III clinical trials [26] . However, all patients ultimately progress on this therapy, so clinical trials of new and better agents and innovative treatment strategies are essential to expand the existing treatment options for patients with cholangiocarcinoma.
Metastases to the liver are more common than primary liver tumors [27] 
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CS-PHP PROCEDURE

Rationale
Delcath Systems has developed a drug/device combination product as a minimally invasive alternative to open-surgical isolated hepatic perfusion (IHP). The product is composed of the chemotherapeutic agent melphalan hydrochloride and a number of sterile, single-use components, including catheters and an extracorporeal circuit with hemofiltration cartridges. The Delcath device is used in a procedure known as CS-PHP to percutaneously deliver a high dose of melphalan to the liver via the hepatic artery, while minimizing systemic exposure to the drug by filtering blood before it is returned to the systemic circulation.
Chemotherapeutic Agent
Melphalan was selected as the chemotherapeutic agent for use with CS-PHP because it showed both efficacy and reversible hepatic toxicity in the treatment of hepatic metastases from a variety of tumors, including melanoma, CRC, HCC, and NETs in the analogous regional procedure of IHP [32] [33] [34] [35] [36] . The principal toxicity of melphalan is bone marrow suppression, including thrombocytopenia, anemia, and neutropenia.
Technique
The Hepatic CHEMOSAT Ò Delivery System is used to conduct CS-PHP. A schematic overview of how the components of the CHEMOSAT Ò Delivery System work together is provided in Fig. 1 CS-PHP should not be performed in patients with any of the following:
• Childs B or C cirrhosis or evidence of portal hypertension by endoscopy or radiologic imaging
• A history of transient ischemic attacks
• Heart failure, with a left ventricular ejection fraction \50%
• Significant chronic obstructive pulmonary disorder or other chronic pulmonary restrictive disease that would make the patient ineligible for general anesthesia
• Body weight \35 kg (because of anatomical and physical limitations with the size of the double-balloon catheter)
• Severe allergic reactions to iodinated contrast that cannot be controlled by antihistamines and steroids
• Prior hypersensitivity reaction to melphalan, a documented latex allergy, or a history of hypersensitivity to heparin or presence of heparin-induced thrombocytopenia antibodies 
Support During and After CS-PHP
Heparin is administered by the anesthesiologist to maintain activated clotting time at therapeutic levels. Heparin is administered at the direction of the interventional radiologist before he/she isolates the liver and prior to the initiation of the extracorporeal circuit by the perfusionist. Vital signs are monitored continuously throughout the procedure by the anesthesiologist. All patients will experience hypotension at two points during the procedure: when the venous balloons are inflated and when the filters in the bypass circuit are activated [37] .
The blood pressure decrease is managed with prehydration, intraoperative fluid boluses, and IV vasopressors until blood pressure normalizes.
Vasopressors are administered by the anesthesiologist to maintain a mean arterial pressure above 65 mmHg to prevent ischemic injury to the heart and brain. 
EVIDENCE FOR EFFECTIVENESS OF CS-PHP
Clinical Trials
The use of CS-PHP with melphalan was tested in a formal clinical trial program that included the following studies:
• Table 2 . The MTD of melphalan delivered by CS-PHP was determined to be 3.0 mg/kg since only one patient had a DLT at this dose. All DLTs were events related to bone marrow suppression, including neutropenia, febrile neutropenia, leukopenia, and thrombocytopenia.
In the phase 2 study ( patients originally assigned to BAC, 28 had hepatic disease progression and crossed over to receive CS-PHP. A post hoc analysis examined outcomes in these patients compared to those in the BAC group who had not crossed over to CS-PHP and those originally assigned to CS-PHP [40] . The baseline characteristics of the crossover group were comparable to the groups who received BAC only and those who were initially randomized to CS-PHP [39] . The analysis of outcomes in this post hoc analysis showed that the efficacy of CS-PHP in the CR complete response, PD progressive disease, PR partial response, SD stable disease a Excluding three patients enrolled, but not treated crossover group was similar to that in the group initially randomized to this therapy. The median hPFS was 8.0 in the CS-PHP group and 1.6 in the BAC group that had not crossed over to CS-PHP (P\0.0001). The crossover group had an hPFS of 8.8 months, which was comparable to that in the group initially treated with CS-PHP. The median OS was 9.8 months in the CS-PHP group as opposed to 4.1 months in the BAC-only group and 15.3 months in the crossover group. As was seen in the phase 2 study, the toxicity profile in the phase 3 study was characterized by adverse events related to bone marrow suppression, including thrombocytopenia, neutropenia, and anemia. Most of these events were not associated with clinical sequelae.
Retrospective Studies
In addition to the results of the clinical trial program, several retrospective studies reported outcomes data for CS-PHP with melphalan (summarized in Table 4 ). A total of four noncomparative studies were conducted [41] [42] [43] [44] . One of the noncomparative studies enrolled 13 patients [44] , 10 of whom were also included in a separate comparative retrospective analysis [45] . In addition, two case reports were published [46, 47] . All of the studies reported hepatic response data; two of the studies also reported toxicity data [41, 43] .
In the noncomparative studies of CS-PHP Toxicity data were reported in the noncomparative study by Vogl et al. [41] . (Table 4) [37] . Liver-directed therapies included yttrium, chemoembolization, and CS-PHP. One patient was treated with yttrium after CS-PHP and one patient was treated with CS-PHP after chemoembolization; both of these patients were excluded from the efficacy analyses.
Table 4
Outcomes data for CS-PHP in the literature [33] [34] [35] [37] [38] [39] Including subset of ten patients from noncomparative study by Rashid et al. [44] Kaplan-Meier survival estimates, log-rank test, and multivariate Cox regression analyses were used to relate patient, tumor, and treatment variables to hPFS and OS.
There were no differences between the yttrium, chemoembolization, and CS-PHP groups with regard to age, adjuvant therapy, prior regional hepatic treatment, or complications following treatment.
Extrahepatic disease was more prevalent in the chemoembolization group (P = 0.004) compared with the yttrium and CS-PHP groups. The ECOG score trended lower in the CS-PHP group (P = 0.051) compared with the yttrium and chemoembolization groups. Median hPFS was significantly (P = 0.002) longer with CS-PHP (310 days) than with yttrium (54 days) and chemoembolization (80 days) [36] . Median hPFS was also significantly longer with CS-PHP versus yttrium (P\0.001) and CS-PHP versus chemoembolization (P = 0.008), but not yttrium versus chemoembolization (P = 0.44).
A higher ECOG score (P = 0.01) and a greater tumor burden (P = 0.03) were correlated with a shorter duration of hPFS. Median OS was longer with CS-PHP (736 days) than with yttrium (285 days) and chemoembolization (265 days); this difference was significant for CS-PHP versus yttrium (P = 0.03). Neither ECOG score nor tumor burden were significant predictors of OS.
Case Reports
Two case reports for CS-PHP with melphalan have been published (Table 4) 
Post-approval Experience with CS-PHP in Europe
As of July 31, 2016, 186 patients in the EU had received a total of 321 CS-PHP treatments (Table 5 ). Most procedures were performed for patients with liver metastases from ocular melanoma. The majority of procedures were performed in Germany (75 procedures total in 11 hospitals), the UK (49 procedures total in four hospitals), and the Netherlands (33 procedures total in two hospitals). CS-PHP was also performed in Italy (12 procedures total in two hospitals), France (nine procedures total in two hospitals), Spain (six procedures total in two hospitals), Ireland (one procedure total in one hospital), and Turkey (one procedure in one hospital 
Ongoing Clinical Studies
A number of clinical studies with CS-PHP are either ongoing or planned. A summary of these studies is provided in Table 6 . 
